January 6, 2021 -- A new joint venture called ScaleReady has been launched to develop tools and technologies for use in cell and gene therapy manufacturing. The firm is a joint venture among Bio-Techne, Fresenius Kabi, and Wilson Wolf.
ScaleReady will provide sales, marketing, and application support for companies manufacturing cell and gene therapy products. Wilson Wolf's G-Rex cell culture technology, Fresenius Kabi's Lovo and upcoming Cue cell processing systems, and Bio-Techne's range of good manufacturing product (GMP) proteins, reagents, media, and gene editing technologies will be included in ScaleReady's manufacturing platform.
ScaleReady is owned equally by the three partners. Financial terms of the venture were not disclosed.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: